These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 11866664)

  • 1. Therapeutic potential of CPT I inhibitors: cardiac gene transcription as a target.
    Zarain-Herzberg A; Rupp H
    Expert Opin Investig Drugs; 2002 Mar; 11(3):345-56. PubMed ID: 11866664
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Functional genomics of pressure-loaded cardiomyocytes: etomoxir in heart failure?].
    Rupp H; Maisch B
    Herz; 2002 Mar; 27(2):166-73. PubMed ID: 12025461
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Modification of sarcoplasmic reticulum gene expression in pressure overload cardiac hypertrophy by etomoxir.
    Zarain-Herzberg A; Rupp H; Elimban V; Dhalla NS
    FASEB J; 1996 Sep; 10(11):1303-9. PubMed ID: 8836044
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sarcoplasmic reticulum function and carnitine palmitoyltransferase-1 inhibition during progression of heart failure.
    Rupp H; Vetter R
    Br J Pharmacol; 2000 Dec; 131(8):1748-56. PubMed ID: 11139455
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The use of partial fatty acid oxidation inhibitors for metabolic therapy of angina pectoris and heart failure.
    Rupp H; Zarain-Herzberg A; Maisch B
    Herz; 2002 Nov; 27(7):621-36. PubMed ID: 12439634
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Etomoxir improves left ventricular performance of pressure-overloaded rat heart.
    Turcani M; Rupp H
    Circulation; 1997 Nov; 96(10):3681-6. PubMed ID: 9396471
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The metabolic modulators, Etomoxir and NVP-LAB121, fail to reverse pressure overload induced heart failure in vivo.
    Schwarzer M; Faerber G; Rueckauer T; Blum D; Pytel G; Mohr FW; Doenst T
    Basic Res Cardiol; 2009 Sep; 104(5):547-57. PubMed ID: 19294446
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dietary medium-chain triglycerides can prevent changes in myosin and SR due to CPT-1 inhibition by etomoxir.
    Rupp H; Schulze W; Vetter R
    Am J Physiol; 1995 Sep; 269(3 Pt 2):R630-40. PubMed ID: 7573566
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Metabolism and the hypertrophied heart of the elderly].
    Rupp H; Rupp TP; Maisch B
    Dtsch Med Wochenschr; 2005 Mar; 130(12):726-30. PubMed ID: 15776359
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CPT-1 inhibition by etomoxir has a chamber-related action on cardiac sarcoplasmic reticulum and isomyosins.
    Vetter R; Rupp H
    Am J Physiol; 1994 Dec; 267(6 Pt 2):H2091-9. PubMed ID: 7810710
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expression and possible role of muscle-type carnitine palmitoyltransferase I during sperm development in the rat.
    Adams SH; Esser V; Brown NF; Ing NH; Johnson L; Foster DW; McGarry JD
    Biol Reprod; 1998 Dec; 59(6):1399-405. PubMed ID: 9828184
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Modification of myosin isozymes and SR Ca(2+)-pump ATPase of the diabetic rat heart by lipid-lowering interventions.
    Rupp H; Elimban V; Dhalla NS
    Mol Cell Biochem; 1994 Mar; 132(1):69-80. PubMed ID: 8078510
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Uncoupling protein-3 mRNA up-regulation in C2C12 myotubes after etomoxir treatment.
    Cabrero A; Alegret M; Sánchez R; Adzet T; Laguna JC; Vázquez M
    Biochim Biophys Acta; 2001 Jun; 1532(3):195-202. PubMed ID: 11470240
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Etomoxir-induced partial carnitine palmitoyltransferase-I (CPT-I) inhibition in vivo does not alter cardiac long-chain fatty acid uptake and oxidation rates.
    Luiken JJ; Niessen HE; Coort SL; Hoebers N; Coumans WA; Schwenk RW; Bonen A; Glatz JF
    Biochem J; 2009 Apr; 419(2):447-55. PubMed ID: 19138173
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Subcellular remodeling and heart dysfunction in cardiac hypertrophy due to pressure overload.
    Dhalla NS; Golfman L; Liu X; Sasaki H; Elimban V; Rupp H
    Ann N Y Acad Sci; 1999 Jun; 874():100-10. PubMed ID: 10415524
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Modification of subcellular organelles in pressure-overloaded heart by etomoxir, a carnitine palmitoyltransferase I inhibitor.
    Rupp H; Elimban V; Dhalla NS
    FASEB J; 1992 Mar; 6(6):2349-53. PubMed ID: 1531968
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Down-regulation of acyl-CoA oxidase gene expression and increased NF-kappaB activity in etomoxir-induced cardiac hypertrophy.
    Cabrero A; Merlos M; Laguna JC; Carrera MV
    J Lipid Res; 2003 Feb; 44(2):388-98. PubMed ID: 12576521
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Improvement of myocardial function and metabolism in diabetic rats by the carnitine palmitoyl transferase inhibitor Etomoxir.
    Schmitz FJ; Rösen P; Reinauer H
    Horm Metab Res; 1995 Dec; 27(12):515-22. PubMed ID: 8750778
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Downregulation of myocardial myocyte enhancer factor 2C and myocyte enhancer factor 2C-regulated gene expression in diabetic patients with nonischemic heart failure.
    Razeghi P; Young ME; Cockrill TC; Frazier OH; Taegtmeyer H
    Circulation; 2002 Jul; 106(4):407-11. PubMed ID: 12135937
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Myocardial contractility after infarction and carnitine palmitoyltransferase I inhibition in rats.
    Günther J; Wagner K; Theres H; Schimke I; Born A; Scholz H; Vetter R
    Eur J Pharmacol; 2000 Oct; 406(1):123-6. PubMed ID: 11011043
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.